

Douglas W Sborov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225004/publications.pdf>

Version: 2024-02-01

33
papers

529
citations

759233

12
h-index

677142

22
g-index

33
all docs

33
docs citations

33
times ranked

859
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955.	7.0	72
2	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	7.2	56
3	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	1.3	43
4	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. <i>Oncotarget</i> , 2015, 6, 31134-31150.	1.8	38
5	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 830-841.	4.1	35
6	In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. <i>Leukemia</i> , 2020, 34, 317-321.	7.2	34
7	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2017, 56, 1722-1732.	2.7	28
8	Financial toxicity in hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, 74.	6.2	22
9	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. <i>BMC Cancer</i> , 2021, 21, 510.	2.6	21
10	Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 74-83.	2.5	20
11	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
12	Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. <i>Blood Advances</i> , 2021, 5, 1097-1101.	5.2	15
13	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. <i>American Journal of Hematology</i> , 2021, 96, 690-697.	4.1	13
14	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13
15	Targeted therapy in sarcomas other than GIST tumors. <i>Journal of Surgical Oncology</i> , 2015, 111, 632-640.	1.7	11
16	Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758.	2.5	11
17	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. <i>Anticancer Research</i> , 2019, 39, 67-72.	1.1	10
18	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. <i>Lancet Haematology</i> , 2021, 8, e299-e304.	4.6	10

#	ARTICLE	IF	CITATIONS
19	Hospitalization at the end of life in patients with multiple myeloma. <i>BMC Cancer</i> , 2021, 21, 339.	2.6	9
20	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 156, 164-174.	2.8	9
21	Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 91-95.	4.9	9
22	Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 519-531.	4.4	8
23	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339.	2.7	7
24	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 44-49.	2.0	4
25	Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. <i>European Journal of Cancer</i> , 2022, , .	2.8	4
26	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211006.	2.5	4
27	Most multiple myeloma patients have low testosterone. <i>Leukemia and Lymphoma</i> , 2019, 60, 836-838.	1.3	3
28	MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8068-TPS8068.	1.6	2
29	Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1816-1816.	1.4	1
30	Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes. <i>Blood</i> , 2021, 138, 1971-1971.	1.4	1
31	Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. <i>Blood</i> , 2013, 122, 3232-3232.	1.4	0
32	Palliative Care Utilization, Transfusion Burden and Symptoms for Patients with Multiple Myeloma at the End of Life. <i>Blood</i> , 2021, 138, 4103-4103.	1.4	0
33	Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. <i>Clinical Hematology International</i> , 2022, 4, 56-59.	1.7	0